Neoplasia hematologikoak: Leuzemiak, Linfomak eta Mielomak

4-AMINOPYRIDINE STRUCTURAL ANALOGUES USEFUL IN THE TREATMENT OF NEOPLASMS

Resumen de: WO2026146397A1

The present invention describes a method for treating a neoplasm comprising administering a 4-aminopyridine (4-AP) structural analogues to a subject in need thereof. In this regard, it was surprisingly found that the 4-AP structural analogues can block potassium channels (Kv channels) overexpressed in the neoplasm inhibiting its cell proliferation and causing cell apoptosis. In a preferred embodiment of the invention, the Kv channels are selected from the group consisting of Kv 1.3, Kv 10.1 and Kv 11.1, which are overexpressed in malignant neoplasms selected from the group consisting of glial tumors, gastric cancer, colon cancer, lymph nodes, breast cancer, ovarian cancer, endometrial cancer, melanoma, glioblastoma, acute lymphoid leukemia, head and neck cancer, glioma, lung cancer, cervical cancer, sarcoma, myeloid leukemia, Lymphoid leukemia, oligodendroglioma, colorectal cancer and neuroblastoma.

NATURAL KILLER CELL ENGAGERS

Resumen de: US20260193362A1

0000 This document relates to methods and materials involved in treating cancer. For example, this document provides cell engagers that bind to natural killer (NK) cells and bind to cancer cells. In some cases, a cell engager provided herein can include a first antigen binding domain having the ability to bind to a NK cell Group 2 isoform C (NKG2C) polypeptide and a second antigen binding domain having the ability to bind to a polypeptide present on the surface of a cancer cell. In some cases, a mammal (e.g., a human) having cancer (e.g., a leukemia such as acute myeloid leukemia (AML)) can be administered one or more cell engagers provided herein to treat the cancer.

USE OF IL-27 ANTAGONISTS FOR THE TREATMENT OF EBV-DRIVEN B LYMPHOPROLIFERATIVE DISEASES

Resumen de: US20260193338A1

Upon EBV infection, the inventors found that IL-27 is produced by infected B lymphocytes and IL27RAIL-27 interaction is required for in vitro maintenance and expansion of EBV-transformed B cells, potentially explaining the favorable outcome of the EBV viral disease in IL27RA-deficient patients. In addition, the inventors identified neutralizing anti-IL27 autoantibodies in individuals who developed sporadic infectious mononucleosis, thus possibly phenocopying the IL27RA deficiency. Collectively, these results demonstrate the critical role of IL27-IL27RA axis in immunity to EBV, but also the hijacking of this defense by EBV to promote expansion of infected cells. The IL27-IL27RA could therefore represent a novel therapeutic target to inhibit EBV-driven B lymphoproliferative diseases.

DETECTING CANCER, CANCER TISSUE OF ORIGIN, AND/OR A CANCER CELL TYPE

Resumen de: AU2026204764A1

The present description provides a hematological disorder (HD) assay panel for targeted detection of methylation patterns or variants specific to various hematological disorders, such as clonal hematopoiesis of indeterminate potential (CHIP) and blood cancers, such as leukemia, lymphoid neoplasms (e.g. lymphoma), multiple myeloma, and myeloid neoplasm. Further provided herein includes methods of designing, making, and using the HD assay panel for detection of various hematological disorders. un u n

PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MULTIPLE MYELOMA, MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE, AND SMOLDERING MULTIPLE MYELOMA

Resumen de: US20260191834A1

A pharmaceutical combination includes a beta-lactam antibiotic alone or in combination with a beta-lactamase inhibitor useful for treating multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma. A method for treating multiple myeloma, monoclonal gammopathy of undetermined significance, or smoldering multiple myeloma includes administering to a patient in need thereof an effective amount of a combination of a beta-lactam antibiotic and a beta-lactamase 2024/102361 inhibitor. Beta-lactam antibiotic for use in combination with a beta-lactamase inhibitor for the treatment of multiple myeloma, monoclonal gammopathy of undetermined significance, or smoldering multiple myeloma in a patient in need of the treatment is also described.

DRUG-LINKER AND ANTIBODY-DRUG CONJUGATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF

Resumen de: WO2026145453A1

Provided are a drug-linker, an antibody-drug conjugate thereof, a preparation method therefor and the use thereof. The drug-linker has a structure as represented by formula (I), and the antibody-drug conjugate has a structure as represented by formula (II). The drug can be selected from a topoisomerase inhibitor, a DNA damage agent, a microtubule inhibitor, an RNA polymerase inhibitor, and an antimetabolic compound. The prepared antibody-drug conjugate exhibits a significant synergistic effect, and achieves a targeted killing effect on breast cancer, gastric cancer, lung cancer, colorectal cancer and lymphoma.

NOVEL TUMOR-SPECIFIC ANTIGENS FOR LYMPHOID LEUKEMIA AND USES THEREOF

Resumen de: US20260191940A1

0000 Lymphoid leukemia such as acute lymphoblastic leukemia (ALL) represents a devastating disease especially when it occurs in adults. While dose-intensification strategies have led to a significant improvement in outcomes for pediatric patients, prognosis for the elderly remains very poor, with only 30-40% of adult patients with ALL achieving long-term remission. Novel tumor-specific antigens (TSAs) shared by a large proportion of lymphoid leukemia cells are described herein. Most of the TSAs described herein derives from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells and vaccines derived from these TSAs are described. The use of the TSAs, nucleic acids, compositions, cells and vaccines for the treatment of leukemia such as lymphoid leukemia is also described.

CAS9 and Reverse Transcriptase Mutants with Improved Activity in Prime Editing Applications

Resumen de: US20260193630A1

This invention pertains to fusion protein mutants comprising a Prime Editing enzyme having a first amino acid sequence and a second amino acid sequence, wherein the first amino acid sequence comprises a SpCas9 H840A nickase mutant protein of SEQ ID NO:152 and the second amino acid sequence comprises a Moloney Murine Leukemia Virus reverse transcriptase protein mutant (MMLV RTase mutant), wherein the fusion protein mutant displays at least the equivalent or greater activity of a reference Prime Editing enzyme in genome editing.

MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF

Resumen de: AU2024408866A1

Some embodiments of the disclosure include compounds of Formula (I) and Formula (la), and compositions thereof, e.g., pharmaceutical compositions, which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain diseases. Some embodiments include methods of using the compounds (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as hematopoietic cancers, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), etc.). Additional embodiments provide disease treatment using combinations of the IRAK and/or FLT3 inhibiting compounds with other therapies, such as cancer therapies.

MULTISPECIFIC-ANTIBODY COMPOSITION, PREPARATION METHOD THEREFOR, AND USE THEREOF

Resumen de: AU2024396133A1

Provided is a composition which can be a lyophilized preparation solution or a lyophilized powder preparation. The composition comprises a multispecific antibody, a surfactant, a buffer system, and a stabilizer/osmotic pressure regulator. Further provided are a preparation method for the composition and use of the composition, for example, use in treating tumors, especially multiple myeloma.

SUBSTITUTED 1-PHENYL-3,4-DIHYDROPYRIDO3,4-DPYRIMIDIN-2-ONE DERIVATIVES

Resumen de: US20260193253A1

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, including but not limited to leukemia.

METHOD FOR QUANTIFYING NEOPLASTIC FOLLICULAR REGULATORY T CELLS AND NEOPLASTIC FOLLICULAR CYTOTOXIC T CELLS, METHOD FOR SCREENING NEOPLASTIC FOLLICULAR REGULATORY T CELLS AND NEOPLASTIC FOLLICULAR CYTOTOXIC T CELLS, THERAPEUTIC COMPOSITION, AND KIT

Resumen de: EP4772880A1

0001 The present invention provides a technique useful for predicting prognosis of patients with follicular lymphoma. The present invention provides a method for quantifying neoplastic follicle regulatory T cells and neoplastic follicle cytotoxic T cells among T cells collected from a subject, for predicting prognosis of follicular lymphoma, the method comprising a flow cytometry step of detecting and enumerating neoplastic follicle regulatory T cells or neoplastic follicle cytotoxic T cells among T cells collected from a subject by a flow cytometry method using an anti-CD4 antibody, an anti-CD8a antibody, an anti-PD-1 antibody, an anti-CD25 antibody, and an anti-TIM-3 antibody, or a multiplex immunostaining step of detecting and enumerating neoplastic follicle regulatory T cells or neoplastic follicle cytotoxic T cells among T cells collected from a subject by a multiplex immunoassay using an anti-CD4 antibody, an anti-CD8 antibody, an anti-PD-1 antibody, an anti-FOXP3 antibody, an anti-TCF-1 antibody, and an anti-Granzyme K antibody.

ANTIBODIES FOR MULTIPLE MYELOMA TREATMENT

Resumen de: US20260184784A1

Cell surface polypeptides SEMA-4A and FCRL3 have been identified as being associated with multiple myeloma. Accordingly, these peptides represent targets for immuno-based therapeutic strategies for treating multiple myeloma. Antibodies that specifically bind to one of these polypeptides can be used to treat multiple myeloma. Accordingly, new compositions and methods utilizing novel antibodies that target SEMA-4A and FCRL3 are described.

DYRK/CLK PROTACS AND USES THEREOF

Resumen de: US20260183407A1

0000 The present invention relates to bifunctional compounds, which find utility to degrade and (inhibit) one or more of the following kinases: DYRK1A, DYRK1B, DYRK2, DYRK3, CLKI, CLK2, CLK3, CLK4, and HASPIN. In particular, the present invention is directed to compounds, which contain on one end an E3 ubiquitin ligase binding moiety which binds to an E3 ubiquitin ligase and on the other end a moiety which binds one or more of the following kinases: DYRK1A, DYRK1B, DYRK2, DYRK3, CLK1, CLK2, CLK3, CLK4, and HASPIN, such that the one or more kinases is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of the one or more kinases. The bifunctional compounds serve as therapeutics for the treatment of Alzheimer's disease, down syndrome, diabetes, an autoimmune disease, an inflammatory disorder (e.g., airway inflammation, osteoarthritis (e.g., knee related osteoarthritis)), cancer (e.g., glioblastoma, prostate cancer, metastatic breast cancer, metastatic lung cancer, multiple myeloma, secondary metastatic tumors of the brain, colorectal cancer), a viral infection (e.g., SARS-COV-2 infection (e.g., COVID-19)), and other diseases.

THERAPEUTIC AGENT FOR MULTIPLE MYELOMA

Resumen de: WO2026140168A1

The present invention relates to the use of a pharmaceutical composition against multiple myeloma, the composition comprising 5-fluoro-2-(4-{7-(1S,3S,4R)-5-methylidene-2-azabicyclo2.2.2octane-3-carbonyl-2,7-diazaspiro3.5nonan-2-yl}pyrimidin-5-yl)oxy-N,N-di(propan-2-yl)benzamide.

REVERSE TRANSCRIPTASE MUTANTS AND USES THEREOF

Resumen de: WO2026143009A1

The present disclosure provides Moloney murine leukemia virus (MMLV) reverse transcriptase (RTase) variants. The present disclosure further provides amino acid positions for mutagenesis of MMLV RTase as well as nucleic acids, kits, compositions, fusion proteins, and methods including MMLV RTase variants.

COMBINATION THERAPY WITH ANTI-CD19/ANTI-CD28 BISPECIFIC ANTIBODY

Resumen de: US20260184787A1

The present invention relates to combination therapies employing an anti-CD20/anti-CD3 bispecific antibody in combination with an anti-CD19/anti-CD28 bispecific antibody and a CD19-targeted 4-1BB (CD137) agonist and the use of these combination therapies for the treatment of B-cell cancer such as diffuse large B cell lymphoma (DLBCL).

BORON-BASED ENOLASE LIGANDS AND METHODS OF USE FOR TREATMENT OF CANCER

Resumen de: US20260183322A1

Pharmaceutical compositions and methods for using boron-based ligands of enolases to treat cancer are disclosed. One such pharmaceutical composition includes a therapeutically effective amount of a ligand of enolase (1) having a general formula III or a pharmaceutically acceptable derivative thereof. The cancer can be a carcinoma, sarcoma, lymphoma, leukemia, or melanoma. The cancer can be prostate cancer.

SYNTHESIS, PHARMACOLOGY AND USE OF NEW WATER-SOLUBLE AND SELECTIVE FMS-LIKE TYROSINE KINASE3 (FLT3) INHIBITORS

Resumen de: US20260184702A1

The present application relates to compounds of formula (I) for inhibiting FLT3. The present application further relates to a composition, preferably pharmaceutical composition, comprising a compound or a pharmaceutically acceptable salt thereof and comprising a pharmaceutically acceptable excipient and/or carrier. The present application also relates to a compound or composition for use in medicine. The present application also relates to a compound or composition for use in a method of preventing or treating cancer, preferably blood cancer, more preferably leukemia, even more preferably acute myeloid leukemia (AML). Furthermore, the present application relates to a method of preparing a compound.

(4-HYDROXY-1-METHYL-7-PHENOXYISOQUINOLINE-3- CARBONYL)AMINOACETIC ACID (ROXADUSTAT) FOR THE TREATMENT OF ANEMIA IN SUBJECTS WITH MYELODYSPLASTIC SYNDROME (MDS)

Resumen de: AU2024383235A1

The present invention relates to the use of roxadustat in the manufacture of a medicament for treating anemia in a subject having anemia associated with myelodysplastic syndrome (MDS). Methods for treating anemia in a subject having anemia associated with myelodysplastic syndrome comprising administering to the subject a therapeutically effective amount of roxadustat, thereby treating the anemia are also described.

SPECIFIC COVALENT INHIBITOR TARGETING CATALYTIC ACTIVE SITE OF MLL1

Resumen de: WO2026138766A1

Provided are a compound for inhibiting mixed lineage leukemia 1 (MLL1), a composition and a method, wherein the compound targets the catalytic active site of MLL1, thereby inhibiting the activity of MLL1.

METHODS OF TREATING MULTIPLE MYELOMA WITH BCMA INHIBITORS IN COMBINATION WITH PROTEASOME INHIBITORS

Resumen de: US20260184801A1

0000 The present disclosure provides methods for treating multiple myeloma. In certain embodiments, the present methods comprise administering to a subject in need thereof a BCMA inhibitor in combination with a proteasome inhibitor. In certain embodiments, the subject has been previously treated with one or more anti-cancer therapies. In certain embodiments, the proteasome inhibitor is carfilzomib.

COMPOUNDS FOR TREATING LYMPHOMA OR A T-CELL MALIGNANT DISEASE

Resumen de: US20260183266A1

The invention relates to tinostamustine for use in the treatment of lymphoma or a T-cell malignant disease. Tinostamustine may cause side effects when administered to a patient, and it is desirable to minimise such effects. The present invention defines an improved treatment, wherein the dose of tinostamustine administered is varied based on the patient's platelet count.

CASITAS B-LINEAGE LYMPHOMA PROTOONCOGENE B (CBL-B) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE

Resumen de: US20260184710A1

Provided herein are compounds of formula (I) and salts and compositions thereof which find utility as modulators of Cbl-b in the treatment of various forms of cancer.

METHOD FOR PREPARING 4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-L-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-L-YL)-3-FLUOROBENZONITRILE

Nº publicación: EP4768083A2 01/07/2026

Solicitante:

CELGENE CORP [US]
Celgene Corporation

Resumen de: EP4768083A2

Provided herein a compound for use in a method of treating multiple myeloma, wherein the compound is Compound 2 of the formula:or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof, and wherein the method comprises administering a therapeutically effective amount of the compound to a patient in need thereof.